• Dr Sophia Karagiannis and her team

    Antibody therapy and biomarker discovery team

    Triple negative breast cancer is a sub-type of the disease for which there are currently no targeted treatments. In addition, this form of breast cancer can be more aggressive than others.

  • Assessing the feasibility of an online support service for secondary breast cancer patients

    Dr Fiona Kennedy will investigate the feasibility of an online resource to offer support to secondary breast cancer patients and help them to manage their symptoms with the ultimate aim of improving their overall quality of life.

  • Breast Development team

    Breast Development team

    Although effective treatments for breast cancer exist, there are many patients for whom these treatments don’t work or stop working over time.

  • Cell Death and Inflammation Team

    Cell Death and Inflammation team

    Cancer cells are extremely resilient and able to survive in harsh conditions, sometimes lingering in the body even after treatment. Finding ways to tackle this resilience will help scientists develop more effective ways to treat breast cancer.

  • Nick Orr

    Complex Trait Genetics group

    The best way to stop people dying from breast cancer is to stop it occurring in the first place. To do this, we need to be able to identify those most at risk of breast cancer and work out what we can do to prevent them from developing it.

  • Dr Rob Falconer

    Designing new potent chemotherapy drugs that exclusively kill cancer cells

    Dr Robert Falconer is developing a new form of chemotherapy, which could only kill cancer cells, leaving healthy cells intact. If this project is successful, it could save lives and lead to more people living beyond breast cancer.

  • Dr John Maher and his lab team

    Developing a safe and effective CAR-T cell immunotherapy for breast cancer

    Dr John Maher is developing a new type of immunotherapy for breast cancer. In this project he is improving a CAR-T cell therapy so that it’s effective against breast cancer cells but doesn’t attack non-cancer cells, ensuring that the treatment is safe for testing in patients.

  • Dr Lyndsay Hughes and her team at King’s College London

    Developing an Electronic-intervention to help people with breast cancer persist with and adhere to anti-hormone therapy (E-PATH)

    People with ER positive breast cancer can be prescribed anti-hormone treatment for five years or more to reduce the risk of recurrence, but many find it hard to complete the course. Dr Hughes’ team are developing a way to help people persist with their treatment.

  • Drug Target Discovery team - Prof Spiros Linardopoulos

    Drug Target Discovery team

    Although effective treatments exist for breast cancer, there are many patients for whom these drugs don’t work or stop working over time. We need to develop the next generation of targeted drugs to ensure that all patients receive the best possible treatment.

  • Endocrinology team

    Endocrinology team

    The Endocrinology team aims to understand how and why some patients’ cancers are resistant and others aren't.